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Abstract
Background: The ε4 allele of the Apolipoprotein E gene (APOE-ε4) is a potent genetic risk factor for sporadic
Alzheimer’s disease (AD). Amnestic mild cognitive impairment (aMCI) is an intermediate state between normal
cognitive aging and dementia, which is easy to convert to AD dementia. It is an urgent problem in the field of
cognitive neuroscience to reveal the conversion of aMCI-ε4 to AD. Based on our preliminary work, we will study the
neuroimaging features in the special group of aMCI-ε4 with multi-modality magnetic resonance imaging (structural
MRI, resting state-fMRI and diffusion tensor imaging) longitudinally.
Methods/Design: In this study, 200 right-handed subjects who are diagnosed as aMCI with APOE-ε4 will be
recruited at the memory clinic of the Neurology Department, XuanWu Hospital, Capital Medical University, Beijing,
China. All subjects will undergo the neuroimaging and neuropsychological evaluation at a 1 year-interval for
3 years. The primary outcome measures are 1) Microstructural alterations revealed with multimodal MRI scans
including structure MRI (sMRI), resting state functional MRI (rs-fMRI), diffusion tensor imaging (DTI); 2)
neuropsychological evaluation, including the World Health Organization-University of California-LosAngeles Auditory
Verbal Learning Test (WHO-UCLA AVLT), Addenbrook’s cognitive examination-revised (ACE-R), mini-mental state
examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating scale (CDR).
Discussion: This study is to find out the neuroimaging biomarker and the changing laws of the marker during the
progress of aMCI-ε4 to AD, and the final purpose is to provide scientific evidence for new prevention, diagnosis and
treatment of AD.
Trial Registration: This study has been registered to ClinicalTrials.gov (NCT02225964, https://www.clinicaltrials.gov/)
in August 24, 2014.
Keywords: APOE4 allele, Alzheimer’s disease, Amnestic mild cognitive impairment, Neuroimaging techniques,
Multimodality, Longitudinal study
Background
Alzheimer’s disease (AD) is a common neurodegenerative
disorder, which is increasingly prevalent among the eld-
erly. AD patients usually complain of memory impairment
and serious decline of the daily living abilities. The aMCI
is an intermediate state between normal cognitive aging
and dementia, which is easily progressed to AD dementia.
Thus, the effective therapy of AD is to be delivered once
the diagnosis is made at the very early stages of AD, ideally
in the phase of aMCI. The human apolipoprotein E
(APOE) gene has three polymorphic alleles (E2, E3, and
E4) [1]. APOE-ε4 was confirmed to be related with spor-
adic AD risks by increasing the risk of developing AD and
reducing the age of onset [2]. Therefore, it is an urgent re-
quirement in the field of cognitive neuroscience to reveal
the underlying neurological mechanism of the conversion
of aMCI to AD in the patients with APOE-ε4.
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Although the cognition evaluation is simple, the accur-
acy of the diagnosis depends on the professional skills of
the doctor and the collaboration of patients. On the
other hand, MRI might be a promising strategy for early
diagnosis of AD [3]. MRI might be the best diagnosis
method for AD by mapping both structures and functions
of the human brain. Structurally, studies showed that
brain atrophy in AD patients first appears in the medial
temporal lobe (MTL), and then involves the parietal lobe,
frontal lobe and occipital lobe, and finally the anterior cin-
gulate cortex [4, 5]. Consistent with these findings, evi-
dence from our team has demonstrated the progressive
alterations of brain structures during the progression to
AD [6]. Compared with APOE-ε4 non-carriers, the car-
riers exhibited greater medial temporal lobe atrophy [7].
APOE-ε4 is an independent risk factor for the hypotrophy
hippocampus in patients with AD and MCI [8]. Decreased
gray matter volume mainly restricts in the right brain area
for aMCI-ε4 patients [9]. Not the degree of atrophy, but
the rate of atrophy in a certain region of brain demon-
strate close relationship with the AD progression [10].
The rate of hippocampal atrophy is suggested to be an
early marker of incipient memory decline and dementia
[11]. The longitudinal study indicated that rate of volu-
metric loss was significantly greater among MCI-ε4 com-
pared with non-carriers [12]. Compared with structural
MRI, diffusion tensor imaging (DTI) is a more sensitive
method for detecting white matter damage [13]. A short-
term follow-up study showed that AD patients had lower
fractional anisotropy (FA) than controls in the fornix and
anterior portion of the cingulum bundle, and these FA
values were positively correlated with cognitive score [14].
The APOE-ɛ4 modulates white matter (WM) before clin-
ical manifestations and cognitive impairment [15]. The
changes of white matter is accompanied with the cognitive
function decline in APOE-ε4 carriers [16]. Previous stud-
ies suggested that rs-fMRI is a potential functional bio-
marker for cognitive impairment. The aMCI subjects
showed that posterior cingulate cortex/precuneus (PCC/
PCu) hyper-functional connectivity was found at baseline,
while a substantial decrease of these connections was ob-
served at follow-up [17]. Our team observed that the
aMCI patients had decreased amplitude of low-frequency
fluctuations (ALFF) values in the PCC/PCu, anterior med-
ial prefrontal cortex (aMPFC), hippocampus/parahippo-
campal gyrus (PHG), basal ganglia, and prefrontal regions,
and increased ALFF values mainly in several occipital and
temporal regions [18]. APOE-ε4 exerts an influence on
brain function in patients with MCI. Using whole-brain
pulsed arterial spin labeling (ASL) magnetic reson-
ance imaging suggest that cognitive status and APOE
genotype have interactive effects on cerebral blood
flow (CBF) [19]. MCI-ε4 patients demonstrated sig-
nificantly increased CBF [20]. However, deficits exist
in these studies that using rs-fMRI to reveal the ef-
fect of APOE-ε4 on MCI patients.
For the purpose of early diagnosis, the researchers
have been focusing on the aMCI window. Although pre-
vious studies provide important information for the con-
version of aMCI to AD, they were based on the single
modality neuroimaging analysis. Moreover, previous
studies ignored one of the major factors that affects the
course of the MCI converting to AD is the APOE-ε4.
Thus, the purpose of the current trial is to longitudinally
investigate the multi-modal (structural MRI, resting
state-fMRI and diffusion tensor imaging) neuroimaging
characteristics of aMCI-ε4 patients. We hope to provide
scientific evidence for more effective prevention, diagno-
sis and treatment of AD.
Methods/Design
The scheme of the current prospective trial is described
in Fig. 1.
Subject
1. Subjects inclusion: subjects with aMCI included the
following: (1) memory complaint, preferably
confirmed by an informant; (2) a single domain or
multi domain cognitive decline; abnormal objective
memory impairment documented by the scores falling
1.5 SD below the age and education matched-specific
norms on memory test; being free from
dementia according to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, revised
(DSM-IV-R); (3) objective memory impairment, cutoff
points of MiniMental State Examination (MMSE)
score: 19 (no formal education), 22 (1 to 6 years of
education), and 26 (7 or more years of education);
cutoff points of Montreal Cognitive Assessment
(MoCA): 13 (no formal education), 19 (1 to 6 years of
education), and 24 (7 or more years of education)
[21]; a Clinical Dementia Rating (CDR) score of 0.5;
(4) the Han nationality, right-handed (the Edinburgh
handedness scale score >40 points); no fixed dentures
and can accept MRI scan; (5) able to complete 3 years
follow-up.
2. Subjects exclusion: (1) those who have a clear
history of stroke; (2) severe depression that led to
mild cognitive impairment (Hamilton Depression
Rating Scale score ≥ 24 points); (3) other nervous
system diseases, which can cause cognitive
impairment (such as brain tumors, Parkinson's
disease, encephalitis, and epilepsy); (4) cognitive
impairment caused by traumatic brain injury;
(5) other systemic diseases, which can cause
cognitive impairment, such as thyroid dysfunction,
severe anemia, syphilis, and HIV; (6) a history of
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Fig 1 Flowchart of the current prospective diagnostic trial
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psychosis or congenital mental growth retardation;
and (7) subjects with contraindications for MRI.
Neuropsychological assessments
All subjects will receive a standardized clinical and neuro-
psychological evaluation, including WHO-UCLA AVLT,
ACE-R, MMSE, MoCA, CDR.
APOE genotype
After the neuropsychological assessments and before the
MRI scan, genomic DNA will be extracted from periph-
eral blood using a Blood Genomic DNA Extraction Kit.
The APOE genotypes will be determined by a restriction
enzyme polymerase chain reaction technique. Only sub-
jects carrying the gene of E3/E4 or E4/E4 will be en-
rolled in this study group.
Magnetic resonance brain imaging
Imaging protocol
Imaging data will be acquired using a 3.0 T Trio Siemens
scanner at XuanWu Hospital, Capital Medical University.
For each participant, conventional brain T1-weighted
(T1WI), T2-weighted (T2WI) and fluid-attenuated inver-
sion recovery (FLAIR) images will be obtained to exclude
serious brain diseases. Brain MR images will be inspected
by an experienced neuroradiologist (with over 5-year
experience).
sMRI. using a sagittal MP-RAGE sequence with the fol-
lowing imaging parameters: TR = 1900 ms; TE = 2.2 ms; in-
version time = 900 ms; flip angle = 9。; FOV= 256 mm×
256 mm; matrix = 256 × 256;176 slices, thickness = 1.0 mm.
rs-fMRI. using an echo-planar imaging sequence with
the following parameters: repetition time (TR) = 2000 ms,
echo time (TE) = 40 ms, flip angle (FA) = 90∘, number of
slices = 28, slice thickness = 4 mm, gap = 1 mm, voxel size
= 4 × 4 × 4 mm3, and matrix = 64 × 64. Participants will be
asked to lie quietly in the scanner with their eyes closed
during data acquisition. Each scan lasted for 478 s.
DTI. using an echo planar imaging (EPI) sequence in
32 independent, non-collinear directions of a b-value =
1000 s/mm2, and one additional image with no diffusion
weighting (b = 0). TR = 11000 ms, TE = 98 ms, flip angle
= 90。, field of view (FOV) = 256 mm × 256 mm, imaging
matrix = 128 × 128, number of slices = 60, and slice
thickness = 2 mm. Three acquisitions will be averaged to
increase the signal-to-noise ratio.
MRI image analysis
sMRI data analysis. Voxel-based morphometry (VBM)
with DARTEL will be used to characterize gray matter
volume (GMV). Voxel-based morphometry with DARTEL
will be performed using SPM8 (Welcome Trust Center for
Neuroimaging, London, UK, http://www.filion.ucl.ac.uk/
spm/software/spm8/). For the analysis of cortical
thickness, we will use the software package of the Mon-
treal Neurological Institute (MNI)(http://wiki.bic.mni.mc-
gill.ca/index.php/CIVET). This process includes structural
image non-uniformity correction, spatial standardization,
tissue segmentation (gray matter, white matter and cere-
brospinal fluid), internal and external surface extraction of
gray matter as well as the definition and measurement of
cortical thickness.
rs-fMRI data analysis. Image preprocessing will be per-
formed by using SPM8 (http://www.fil.ion.ucl.ac.uk/
spm/) and Data Processing Assistant for Resting-State
fMRI. The preprocessing procedures will be performed
including removal of the first 10 volumes, slice timing,
and head motion correction. All rs-fMRI data will be
satisfied the criteria of spatial movement in any direc-
tion < 3 mm or 3o and the subjects will be demon-
strated no significant group differences in the head
motion parameters (i.e, three translation and three ro-
tation parameters). To normalize the fMRI data
spatially, the T1-weighted images will be firstly regis-
tered to the mean functional data, and the resulting
aligned T1 data set will be segmented and transformed
into MNI space using the DARTEL toolbox, and a
group template will be generated. Next, the motion-
corrected functional volumes will be specially normalized
to the group template using the transfer parameter esti-
mated by DARTEL segmentation and resampled to 3 mm
isotropic voxels. Further, the functional images will be
spatially smoothed with a 4 mm Gaussian kernel. The
linear detrend and temporal bandpass filtering (0.01 –
0.08 Hz) will be performed to reduce the influences of low-
frequency drift and high-frequency physiological noise.
Finally, several nuisance signals will be regressed out from
the data, including the six motion parameters, the global,
the white matter, and the cerebrospinal fluid signals.
Functional connectivity (FC) analysis using DPARSF
software (http://www.restfmri.net/forum/DPARSF).
DTI data analysis. DTI data processing will be carried
out using FSL software (FMRIB Software Library, http://
www.fmrib.ox.ac.uk/fsl). Initially, eddy current correc-
tion will be run to correct gradient-coil distortions and
small-head motions using affine registration to a refer-
ence image (b0 volume). The brain voxels of DTI data
will be extracted using the Brain Extraction Tool (BET).
The maps of diffusion tensor parameters including FA
and MD will be calculated using DTI-FIT tool, which
fits a diffusion tensor model to diffusion-weighted im-
ages for each voxel. Voxel-wise statistical analysis of the
FA and MD data will be performed for regional differ-
ences using TBSS.
Follow up
All aMCI-ε4 patients will undergo a follow-up review of ap-
proximately 3 years with 1-year interval. They will get the
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entire clinical examination, neuropsychological assessment
and MRI scan during the baseline period. Individuals will
come back to the XuanWu Hospital once 1 year for coun-
tercheck. All the evaluations are the same as that they re-
ceive during the first clinic visit. According to the diagnosis
in the follow-up stage, aMCI-ε4 patients will be divided into
converters and nonconverters to AD.
Sample size calculation and statistics
A total of 1000 right-handed aMCI patients will be re-
cruited in this study. aMCI-ε4 patients is about 26.6 %,
and annual conversion rate of aMCI-ε4 patients convert
is 15.9 % [22]. Thus, we plan to recruit 200 patients with
aMCI-ε4. There will be about 90 aMCI-ε4 converted
into AD after 3 years of follow-up.
Demographics and clinical characteristics of the subjects
will be analyzed using SPSS 17.0. Two-sample two-tail t test
or two-tail Pearson chi-square test will be used to explore
differences of these data among two groups (converters and
nonconverters). P < 0.05 is considered as with statistical
significance.
For images analysis. To determine the difference be-
tween two groups (converters and nonconverters), we
will perform a two-sample t-test. The significant level
will be set at P < 0.05.
To determine the difference between intra-groups, we
will perform a One-way analysis of variance (ANOVA).
Further, Dunnett-t test will be performed for differences
among intra-groups. The statistical threshold of the two
test will both be set at P <0.05.
Discussion
To our know, APOE-ε4 is a strong risk factor of AD.
However, there has controversy about the effect of
APOE-ε4 on the conversion of aMCI-ε4 to AD. A multi-
variate Cox regression model demonstrated that posses-
sion of an APOE-ε4 was the strongest predictor of
clinical progression among aMCI [23]. Other studies of
have found limited clinical applicability for prediction of
outcome among aMCI [24, 25]. Moreover, Stern et al
implied that APOE-ε4 is associated with a less aggressive
form of AD [26]. Thus, previous studies have shown that
simply depending on the psychometric tests will cause a
noisy clinical data, and need biomarker to clarify the
pathogenic mechanism of APOE-ε4, such as MRI, PET
(positron emission tomography), and cerebrospinal fluid
(CSF) examinations. Comparing to PET and CSF examina-
tions, MRI ─ a noninvasive, nonradiation means ─ has
been widely used with easy patient acceptance in both
clinical and scientific studies.
Some limitations have to be took into account about
this study. First, the trial's follow up time may be too
short to be sured whether MCI-nonconverter would
convert to AD in the future. Therefore, we will plan to
continue to track the dynamic situations of these pa-
tients. Second, there has many technical problems of
MRI. Data acquisition, data processing and data analysis
of MRI are lack of standards. So far, no MRI model can
be used for clinical diagnosis of AD. But we deeply be-
lieve that with the development of neuroimaging, diag-
nosis of AD with MRI will achieve better performance.
Here, this present study is to find out the neuroimag-
ing biomarker and the changing laws of the marker dur-
ing the progress of aMCI-ε4 to AD, and the final
purpose is to provide scientific evidence for new preven-
tion, diagnosis and treatment of AD.
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